Watch out, As­traZeneca: UCB un­corks late-stage suc­cess for $2.1B Soliris ri­val

Just over two years af­ter spend­ing more than $2 bil­lion to ac­quire the drug, UCB an­nounced that zilu­coplan proved ef­fec­tive at treat­ing the rare au­toim­mune dis­ease myas­the­nia gravis in a large Phase III tri­al.

Al­though UCB de­clined to share any spe­cif­ic num­bers, the Bel­gian phar­ma said pa­tients on the drug showed sig­nif­i­cant im­prove­ment over place­bo on all pri­ma­ry and sec­ondary end­points, no­tably in­clud­ing three dif­fer­ent scales used to track symp­toms of the com­plex dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.